# US Polyp Biopsy Market > US Polyp Biopsy Market Research Report By Type (Colonoscopy, Colposcopy-Directed Biopsy, Esophagogastroduodenoscopy, Laryngoscopy), By Distribution Channel (Online Sales Channels, Retail Pharmacies, Others) and By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Organizations) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.51% - **2024:** $ 0.38 Million - **2025:** $ 0.4 Million - **2035:** $ 0.69 Million - **Key Players:** Medtronic (US), Boston Scientific (US), Olympus Corporation (JP), Fujifilm Holdings Corporation (JP), Cook Medical (US), Conmed Corporation (US), Hologic (US), Stryker Corporation (US), B. Braun Melsungen AG (DE) **Report ID:** MRFR/MED/18470-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-polyp-biopsy-market-20017 --- ## Market Summary ## **US Polyp Biopsy Market Overview** As per MRFR analysis, the US Polyp Biopsy Market Size was estimated at 91.14 (USD Million) in 2023. The US Polyp Biopsy Market Industry is expected to grow from 98.7(USD Million) in 2024 to 746.9 (USD Million) by 2035. The US Polyp Biopsy Market CAGR (growth rate) is expected to be around 20.2% during the forecast period (2025 - 2035). ### **Key US Polyp Biopsy Market Trends Highlighted** The US Polyp Biopsy Market is experiencing significant trends driven by an increasing awareness of colorectal cancer and the rising incidence of polyps detected during routine screenings. The US Preventive Services Task Force recommends regular screening for colorectal cancer, contributing to a surge in diagnostic procedures, including polyp biopsies. The rising prevalence of obesity, sedentary lifestyles, and dietary factors are key market drivers, as these conditions are often linked to higher risks of colorectal polyps. Additionally, advancements in endoscopic technologies and techniques are enhancing the effectiveness and accuracy of polyp biopsies, making them more appealing to healthcare providers and patients alike. Opportunities in the US Polyp Biopsy Market can be further explored through the development of minimally invasive procedures and the integration of artificial intelligence in pathological analysis to improve diagnostic accuracy. With a focus on patient-centered care, there is also potential for novel biopsy technologies that minimize discomfort and promote quicker recovery times. Patient education campaigns aimed at increasing screening adherence and participation can play a crucial role in promoting early detection and intervention. Recent trends include increased governmental and institutional support for colorectal cancer awareness campaigns, which are essential in driving screening rates. This reflects a larger societal push towards preventive healthcare and early detection methods. Furthermore, there is a notable shift towards personalized medicine in colorectal health, meaning that biopsy results are increasingly used to tailor treatment plans based on individual patient profiles. All these elements indicate a dynamic environment in the US Polyp Biopsy Market, focusing on improving patient outcomes and advancing technology in the field. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Polyp Biopsy Market Drivers** ### **Increasing Incidence of Colorectal Cancer** The United States has seen a significant rise in the incidence of colorectal cancer, which is a primary factor driving the US [Polyp Biopsy Market](../../../reports/polyp-biopsy-market-1673) Industry. The American Cancer Society reported that in 2021 alone, approximately 104,270 new cases of colon cancer were diagnosed, and evidence suggests this trend is likely to continue with an annual increase of nearly 1% among adults over 50 years of age. This surge in colorectal cancer cases necessitates more frequent and advanced biopsy procedures to detect polyps early and prevent cancer progression. Moreover, established organizations such as the Centers for Disease Control and Prevention (CDC) are actively promoting screening measures and guidelines, further catalyzing the growth of the polyp biopsy market in the US. These efforts underscore the increasing demand for effective diagnostic solutions, directly influencing the market's future prospects and expansion. ### **Advancements in Diagnostic Technologies** The US Polyp Biopsy Market Industry is experiencing growth due to advancements in diagnostic technologies, including high-definition endoscopy and molecular diagnostics. The improvement in these technologies enhances the accuracy and efficiency of polyp detection and biopsy procedures. According to the National Institute of Health, high-definition endoscopic techniques have increased the detection rate of small polyps by over 30% compared to traditional methods. This transition to advanced technologies encourages healthcare providers to opt for more effective biopsy solutions, driving market growth. The overall emphasis on precision medicine and personalized diagnostics also aligns with the increasing budget allocations for Research and Development (R&D) interventions in the US healthcare system, further propelling the demand for innovative biopsy techniques. ### **Rising Awareness and Health Initiatives** Rising public awareness about colorectal health and preventative screenings is significantly boosting the US Polyp Biopsy Market Industry. Campaigns led by organizations such as the American Cancer Society and the CDC advocate for routine screening, particularly among populations at risk. National statistics indicate that approximately 70% of adults aged 50 and above have been screened for colorectal cancer, reflecting an increase in awareness over the past decade. Furthermore, enhanced healthcare policies fostering early detection initiatives underscore the critical role of awareness programs in promoting screening, which in turn drives demand for polyp biopsies. This cultural shift towards preventive healthcare is translating into increased utilization of biopsy services across the country. ## **US Polyp Biopsy Market Segment Insights** ### **Polyp Biopsy Market Type Insights** The US Polyp Biopsy Market, classified by Type, encompasses a variety of procedures critical for accurate diagnosis and screening of polyps. One dominant procedure in this segment is Colonoscopy, which plays a significant role in colorectal cancer prevention by enabling the detection and removal of polyps before they can develop into cancerous lesions. With rising awareness about colorectal cancer and its prevention, this method has seen a substantial increase in adoption rates across the US. Likewise, Colposcopy-Directed Biopsy serves as another essential component, particularly in gynecological examinations, where it allows for effective screening of cervical abnormalities. The focus on early detection of cervical cancer contributes to this procedure's importance and its growing utilization among healthcare professionals. Additionally, Esophagogastroduodenoscopy is utilized for upper gastrointestinal examinations, helping identify and address polyps in the esophagus and stomach, which are critical given the increasing prevalence of gastrointestinal disorders among the US population. The procedure not only aids in diagnosis but also allows for therapeutic interventions. Furthermore, Laryngoscopy, although less prevalent than the previously mentioned procedures, remains vital for examining laryngeal structures and identifying potential polypoid lesions, particularly in patients with voice disorders or chronic hoarseness. Keeping in mind the diverse utility and importance of these biopsy types, the US Polyp Biopsy Market showcases a robust framework that addresses various health concerns. Each type plays a unique role in the broader scope of polyp detection and management, underlining the collective effort toward improved patient outcomes and increased screenings as part of preventive healthcare initiatives in the region. This market growth is significantly influenced by the rising demand for early intervention, technological advancements, and increasing healthcare expenditure in the US. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Polyp Biopsy Market Distribution Channel Insights** The Distribution Channel segment of the US Polyp Biopsy Market plays a crucial role in facilitating access to necessary medical procedures and products. The market has seen significant growth due to the rising prevalence of colorectal cancer and increasing awareness about early detection among the US population. Online Sales Channels have emerged as a prominent force, offering convenience and accessibility for patients seeking at-home tests, thus fostering greater patient engagement in their health. Retail Pharmacies are essential as they provide a familiar touchpoint for patients, allowing them to obtain products recommended by healthcare professionals conveniently. Additionally, other channels contribute to the distribution landscape, catering to specific needs and niches within the market. As health trends evolve, consumers are increasingly turning towards both online shopping and traditional retail for their healthcare needs, reflecting broader patterns in consumer behavior and the impact of digital transformation on the healthcare industry. Various advancements in technology and logistics for distribution further support the overall market growth, addressing challenges like product availability and efficient delivery. This diversification in the distribution channel is critical for reaching a wider audience and enhancing the overall efficacy of colon health management in the country. ### **Polyp Biopsy Market End User Insights** The US Polyp Biopsy Market has shown significant growth across various End User segments, primarily driven by the increasing prevalence of colorectal cancer among the population. Hospitals and Clinics play a crucial role in diagnostics and treatment, as they are often the first healthcare points where patients receive care. This segment is characterized by advanced medical facilities that can provide comprehensive endoscopic services, making it vital for timely polyp detection and management. Diagnostic Centers are also pivotal, offering specialized services in diagnostic imaging and pathology, thus supporting faster and accurate diagnoses. They contribute significantly to efficiency in detecting polyps and are often equipped with cutting-edge technologies. Academic and Research Organizations enhance the sector by driving innovations and advancements in biopsy techniques and methodologies. They play a fundamental role in developing new protocols and treatments through extensive Research and Development, ultimately contributing to improved patient outcomes. Overall, these segments combine to form a robust framework that supports the US Polyp Biopsy Market, addressing both the needs of patients and the advancements in medical technology. ## **US Polyp Biopsy Market Key Players and Competitive Insights** The US Polyp Biopsy Market is characterized by a competitive landscape that reflects a growing emphasis on technological advancements and innovative solutions aimed at improving patient outcomes. This market has gained traction due to the increasing incidence of colorectal cancer, which accelerates the demand for effective screening and early detection measures. Medical professionals are continually seeking state-of-the-art biopsy tools and methodologies that enhance diagnostic accuracy and procedural efficiency. The competitive insights within this sector reveal the dynamics of market players striving for dominance through product differentiation, strategic partnerships, and adherence to regulatory standards that ensure both quality and safety in medical devices. Hologic has established a strong foothold in the US Polyp Biopsy Market, driven by its commitment to innovation and excellence. The company is well-known for its advanced imaging systems and minimally invasive biopsy technologies that empower healthcare providers to conduct precise and efficient procedures. Hologic’s strengths lie in its robust product portfolio, which encompasses a range of biopsy devices designed to cater to various clinical needs. The company’s focus on research and development facilitates the introduction of cutting-edge solutions that not only comply with regulatory requirements but also address the evolving needs of healthcare professionals. Moreover, Hologic’s strategic alliances and collaborations with leading healthcare institutions further enhance its market presence, allowing for broader distribution and adoption of its products. C.R. Bard plays a significant role in the US Polyp Biopsy Market, recognized for its extensive range of medical devices, particularly in the biopsy segment. The company's key offerings include a variety of biopsy needles and accessories that are designed for greater accuracy and patient comfort. C.R. Bard benefits from a strong reputation for quality and reliability, which has fortified its position in a competitive marketplace. The company has also engaged in strategic mergers and acquisitions to expand its product line and enhance its market presence, allowing for the integration of innovative technologies into its offerings. This proactive approach has enabled C.R. Bard to maintain its competitive edge while continuing to address the specific demands of medical professionals and patients in the US. By focusing on delivering superior products and leveraging its operational strengths, C.R. Bard has successfully positioned itself as a key player within the US Polyp Biopsy Market. ### **Key Companies in the US Polyp Biopsy Market Include** - Hologic - C.R. Bard - EndoChoice - Medline Industries - Medtronic - Boston Scientific - Abbott Laboratories - Conmed Corporation - Olympus Corporation - Stryker Corporation - Cook Medical - Pentax Medical - **[Johnson and Johnson](https://www.jnj.com/healthcare-products)** - Intuitive Surgical ## **US Polyp Biopsy Market Industry Developments** The US Polyp Biopsy Market has seen notable developments recently, particularly with advancements in biopsy technology and increasing demand for colorectal cancer screening. In December 2022, Medtronic launched a new device aimed at enhancing the accuracy of polyp removal, thereby supporting improved patient outcomes. Moreover, Hologic has been focusing on expanding its product line, introducing innovative solutions for gastroenterology applications in the realm of polyp detection. Growth in market valuation has been reported across key players such as C.R. Bard and Boston Scientific, reflecting a heightened focus on R&D and effective marketing strategies to boost their presence in this critical healthcare segment. Notably, in February 2023, Abbott Laboratories announced its acquisition of a digital pathology firm, which is expected to enhance its capabilities in guiding polyps detection and diagnosis. In the past two years, the US market has experienced a surge in public awareness regarding the importance of colorectal screenings, leading to an increase in procedures and devices being utilized for effective diagnosis and treatment. This awareness underscores the shift towards preventive healthcare measures within the US medical landscape. ## **US Polyp Biopsy Market Segmentation Insights** ### **Polyp Biopsy Market Type Outlook** - Colonoscopy - Colposcopy-Directed Biopsy - Esophagogastroduodenoscopy - Laryngoscopy ### **Polyp Biopsy Market Distribution Channel Outlook** - Online Sales Channels - Retail Pharmacies - Others ### **Polyp Biopsy Market End User Outlook** - Hospitals & Clinics - Diagnostic Centers - Academic & Research Organizations ## Market Drivers ### Growing Geriatric Population The aging population in the US is a significant driver of the polyp biopsy market. As individuals age, the risk of developing colorectal polyps and cancer increases, making regular screenings essential. The US Census Bureau projects that by 2030, all baby boomers will be over 65 years old, leading to a substantial rise in the geriatric population. This demographic shift is likely to result in a higher demand for polyp biopsy procedures, as older adults are encouraged to undergo routine screenings. The polyp biopsy market is expected to adapt to this growing need by enhancing services tailored to the elderly, including mobile screening units and specialized care. Additionally, healthcare policies promoting preventive care for seniors may further stimulate the market, ensuring that this vulnerable population receives timely and effective diagnostic services. ### Increased Healthcare Expenditure The rising healthcare expenditure in the US is a crucial factor propelling the polyp biopsy market. With healthcare spending projected to reach approximately $4.3 trillion by 2025, there is a growing investment in diagnostic services, including polyp biopsies. This increase in funding allows for the adoption of advanced technologies and improved healthcare infrastructure, facilitating better access to screening and diagnostic procedures. As patients become more willing to invest in their health, the demand for polyp biopsy services is expected to rise. The polyp biopsy market stands to benefit from this trend, as healthcare providers expand their offerings to meet the needs of a more health-conscious population. Furthermore, insurance coverage for preventive services is likely to enhance patient access to polyp biopsies, further driving market growth. ### Advancements in Biopsy Techniques Innovations in biopsy techniques are significantly influencing the polyp biopsy market. The introduction of minimally invasive procedures, such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), has improved the accuracy and safety of polyp biopsies. These advancements allow for the removal and analysis of polyps with reduced patient discomfort and shorter recovery times. As a result, healthcare providers are increasingly adopting these techniques, which may lead to a surge in the number of procedures performed. The polyp biopsy market is likely to see a shift towards these advanced methodologies, as they not only enhance diagnostic capabilities but also improve patient outcomes. Additionally, the integration of imaging technologies, such as narrow-band imaging (NBI), further supports the growth of the market by enabling better visualization of polyps during procedures. ### Rising Incidence of Colorectal Cancer The increasing incidence of colorectal cancer in the US is a primary driver for the polyp biopsy market. According to the American Cancer Society, colorectal cancer is the third most common cancer, with an estimated 104,270 new cases expected in 2023. This alarming trend necessitates enhanced screening and diagnostic measures, including polyp biopsies, to detect precancerous lesions early. As healthcare providers emphasize early detection, the demand for polyp biopsy procedures is likely to rise. Furthermore, the polyp biopsy market is expected to benefit from increased funding for cancer research and awareness campaigns aimed at educating the public about the importance of regular screenings. This growing focus on colorectal health may lead to a more proactive approach in managing and preventing colorectal cancer, thereby driving market growth. ### Enhanced Awareness and Education Initiatives Enhanced awareness and education initiatives regarding colorectal health are playing a pivotal role in the growth of the polyp biopsy market. Various organizations, including the American Cancer Society, are actively promoting awareness campaigns aimed at educating the public about the importance of early detection and screening for colorectal cancer. These initiatives are likely to lead to increased screening rates, as individuals become more informed about the risks associated with colorectal polyps. The polyp biopsy market is expected to benefit from this heightened awareness, as more patients seek out diagnostic services. Furthermore, educational programs targeting healthcare providers may improve the quality of care and increase the number of polyp biopsies performed, ultimately contributing to market expansion. ## Future Outlook The [Polyp Biopsy Market](https://www.marketresearchfuture.com/reports/polyp-biopsy-market-1673) is projected to grow at a 5.51% CAGR from 2025 to 2035, driven by technological advancements, increasing screening rates, and rising awareness of colorectal health. **New opportunities:** - Development of AI-driven diagnostic tools for enhanced accuracy Expansion of telehealth services for remote biopsy consultations Investment in biodegradable biopsy devices to reduce environmental impact By 2035, the polyp biopsy market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Colonoscopy (Largest) vs. Laryngoscopy (Fastest-Growing) In the US polyp biopsy market, colonoscopy remains the largest segment, dominating the market share due to its widespread use in colorectal cancer screening and diagnosis. Colposcopy-directed biopsy follows as a significant segment, especially in gynecological applications, while esophagogastroduodenoscopy and laryngoscopy cater to more specialized medical procedures. The market distribution indicates a strong preference for colorectal examination techniques as crucial preventive strategies. Growth trends in this segment are driven by increasing awareness of preventive healthcare and advancements in medical technology. Colonoscopy is expected to sustain significant usage owing to regulatory recommendations for regular screenings. Meanwhile, laryngoscopy is gaining traction as the fastest-growing segment, attributed to rising incidences of head and neck cancers and increased diagnostic requirements within ENT practices. Colonoscopy (Dominant) vs. Laryngoscopy (Emerging) Colonoscopy is regarded as the dominant technique in the US polyp biopsy market, primarily due to its effectiveness in early detection of colorectal polyps and cancers. This segment benefits from established protocols and insurance coverage promoting its use. Laryngoscopy, while currently emerging, is witnessing rapid adoption, fueled by the need for thorough examination and diagnosis of laryngeal pathologies. The expansion of outpatient procedures and improved laryngoscopic devices is supporting its growth. Additionally, the increased emphasis on early detection of throat-related diseases anticipates a rise in its utilization, making it a notable contender in the evolving landscape of biopsy techniques. ### By Distribution Channel: Online Sales Channels (Largest) vs. Retail Pharmacies (Fastest-Growing) The US polyp biopsy market exhibits a varied distribution across its channels, with online sales channels holding a significant share due to the convenience and accessibility they offer to healthcare providers and patients. Retail pharmacies also play a crucial role, accounting for a growing proportion of the market as they enhance availability and service in local areas. The lesser-known channels encompass specialized medical supply distributors and hospitals, which present opportunities for niche growth as they adapt to emerging healthcare trends. In recent years, the shift towards online sales channels has been propelled by the increasing reliance on digital solutions in the healthcare sector. As telemedicine gains traction, online ordering becomes essential in ensuring timely access to polyp biopsy kits. Additionally, retail pharmacies are becoming the fastest-growing segment due to their expanding services, allowing patients to obtain their biopsy products with greater ease. This dual approach fosters a flexible market landscape that can quickly adapt to changing consumer preferences and technological advancements. Online Sales Channels (Dominant) vs. Retail Pharmacies (Emerging) Online sales channels represent the dominant force in the distribution landscape of the US polyp biopsy market, benefiting from technological advancements and a growing preference among consumers for convenient purchasing options. These channels provide significant advantages, including faster delivery times and broader product ranges, appealing to both healthcare providers and patients alike. In contrast, retail pharmacies are emerging as a vital player in this segment, leveraging their physical presence and personalized services to capture a growing customer base. The retail format's ability to provide rapid access to essential products enhances its emerging status, as it aligns closely with consumer demands for accessibility and service. ### By End-User: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing) The US polyp biopsy market is predominantly driven by hospitals and clinics, which hold a significant share due to their extensive resources and capabilities. These institutions are well-equipped to conduct polyp biopsies, offering superior diagnostic services and access to advanced technologies. Diagnostic centers are also emerging as a crucial segment, increasingly capturing market attention with their specialized services designed for outpatient care. Their accessibility and focus on diagnostic accuracy are key factors contributing to their growing market presence. In recent years, growth trends within the end-user segment have been fueled by advancements in biopsy techniques and increasing awareness about colorectal health. Hospitals and clinics maintain their dominance by providing comprehensive care and integration with surgical pathways. Meanwhile, diagnostic centers are rapidly expanding due to investments in technology and patient-centric approaches, making them ideal partners for healthcare facilities aiming to enhance diagnostic precision and efficiency. Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging) Hospitals and clinics represent the dominant force in the end-user segment, attributed to their robust infrastructure and integrated care models that facilitate comprehensive patient management. They typically offer a wide range of services, making them the first point of contact for patients requiring polyp biopsies. Conversely, diagnostic centers are emerging as specialized entities that emphasize tailored diagnostic services for patients with specific needs. These centers leverage cutting-edge technology and focus on delivering rapid and accurate diagnoses, making them increasingly popular among patients and healthcare providers alike. As awareness of colorectal health issues continues to rise, these centers are well-positioned to capture a growing share of the market. ## Competitive Benchmarking The polyp biopsy market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on enhancing patient outcomes. Key players such as Medtronic (US), Boston Scientific (US), and Olympus Corporation (JP) are at the forefront, each employing distinct strategies to solidify their market positions. Medtronic (US) emphasizes technological advancements in biopsy devices, aiming to improve diagnostic accuracy and patient safety. Meanwhile, Boston Scientific (US) focuses on expanding its product portfolio through strategic acquisitions, thereby enhancing its capabilities in minimally invasive procedures. Olympus Corporation (JP) leverages its expertise in imaging technologies to develop advanced endoscopic solutions, which are crucial for effective polyp detection and biopsy procedures. Collectively, these strategies contribute to a dynamic competitive environment, where innovation and operational efficiency are paramount.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain resilience. This approach appears to be particularly relevant in the context of the polyp biopsy market, which is moderately fragmented, with several players vying for market share. The collective influence of these key players is significant, as they not only drive technological advancements but also set industry standards that smaller companies must adhere to in order to remain competitive. In October Medtronic (US) announced the launch of a new biopsy device that integrates AI technology to assist in real-time decision-making during procedures. This strategic move is likely to enhance the precision of polyp detection and improve patient outcomes, positioning Medtronic as a leader in innovation within the market. The integration of AI into medical devices is a trend that is gaining traction, suggesting a shift towards more intelligent and responsive healthcare solutions. In September Boston Scientific (US) completed the acquisition of a smaller biotech firm specializing in advanced imaging technologies. This acquisition is expected to bolster Boston Scientific's capabilities in the polyp biopsy segment, allowing for enhanced visualization during procedures. The strategic importance of this move lies in its potential to improve procedural outcomes and expand the company's market reach, thereby reinforcing its competitive position. In August Olympus Corporation (JP) entered into a partnership with a leading software company to develop a cloud-based platform for data management in endoscopic procedures. This collaboration is indicative of a broader trend towards digitalization in the healthcare sector, where data analytics and cloud solutions are becoming integral to improving operational efficiencies and patient care. The strategic importance of this partnership lies in its potential to streamline workflows and enhance the overall quality of care in polyp biopsy procedures. As of November the competitive trends in the polyp biopsy market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are playing a crucial role in shaping the current landscape, enabling companies to leverage complementary strengths and enhance their market offerings. Looking ahead, it is anticipated that competitive differentiation will evolve, with a notable shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This evolution suggests that companies that prioritize these aspects will likely emerge as leaders in the polyp biopsy market. ## Recent News & Developments The US Polyp Biopsy Market has seen notable developments recently, particularly with advancements in biopsy technology and increasing demand for colorectal cancer screening. In December 2022, Medtronic launched a new device aimed at enhancing the accuracy of polyp removal, thereby supporting improved patient outcomes. Moreover, Hologic has been focusing on expanding its product line, introducing innovative solutions for gastroenterology applications in the realm of polyp detection. Growth in market valuation has been reported across key players such as C.R. Bard and Boston Scientific, reflecting a heightened focus on R&D and effective marketing strategies to boost their presence in this critical healthcare segment. Notably, in February 2023, Abbott Laboratories announced its acquisition of a [digital pathology](https://www.marketresearchfuture.com/reports/digital-pathology-market-1955)firm, which is expected to enhance its capabilities in guiding polyps detection and diagnosis. In the past two years, the US market has experienced a surge in public awareness regarding the importance of colorectal screenings, leading to an increase in procedures and devices being utilized for effective diagnosis and treatment. This awareness underscores the shift towards preventive healthcare measures within the US medical landscape. ## Report Scope | MARKET SIZE 2024 | 0.384(USD Million) | | --- | --- | | MARKET SIZE 2025 | 0.405(USD Million) | | MARKET SIZE 2035 | 0.693(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.51% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Medtronic (US), Boston Scientific (US), Olympus Corporation (JP), Fujifilm Holdings Corporation (JP), Cook Medical (US), Conmed Corporation (US), Hologic (US), Stryker Corporation (US), B. Braun Melsungen AG (DE) | | Segments Covered | Type, Distribution Channel, End-User | | Key Market Opportunities | Advancements in minimally invasive techniques enhance diagnostic accuracy in the polyp biopsy market. | | Key Market Dynamics | Technological advancements and regulatory changes drive growth in the polyp biopsy market, enhancing diagnostic accuracy and patient outcomes. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US polyp biopsy market in 2024?** A: The overall market valuation was $0.384 Million in 2024. **Q: What is the projected market valuation for the US polyp biopsy market in 2035?** A: The projected valuation for 2035 is $0.693 Million. **Q: What is the expected CAGR for the US polyp biopsy market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 5.51%. **Q: Which companies are considered key players in the US polyp biopsy market?** A: Key players include Medtronic, Boston Scientific, Olympus Corporation, and others. **Q: What segment had the highest valuation in the US polyp biopsy market in 2024?** A: Colonoscopy had the highest valuation at $0.346 Million in 2024. **Q: How do online sales channels perform in the US polyp biopsy market?** A: Online sales channels were valued at $0.174 Million in 2024. **Q: What is the valuation of the hospitals and clinics segment in the US polyp biopsy market?** A: The hospitals and clinics segment was valued at $0.384 Million in 2024. **Q: What is the projected growth trend for the colposcopy-directed biopsy segment?** A: The colposcopy-directed biopsy segment is expected to grow from $0.173 Million in 2024. **Q: How does the diagnostic centers segment compare to other end-users in the market?** A: The diagnostic centers segment was valued at $0.192 Million in 2024, indicating moderate performance. **Q: What distribution channel had the highest valuation in the US polyp biopsy market in 2024?** A: Retail pharmacies had the highest valuation at $0.346 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-polyp-biopsy-market-20017*